

**Clinical Policy: Aflibercept (Eylea, Eylea HD), Aflibercept-mrbb (Ahzantive), Aflibercept-abzv (Enzeevu), Aflibercept-boav (Eydenzelt), Aflibercept-yszy (Opuviz), Aflibercept-ayyh (Pavblu), Aflibercept-jbvf (Yesafili)**

Reference Number: CP.PHAR.184

Effective Date: 03.01.16

Last Review Date: 02.26

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Aflibercept (Eylea<sup>®</sup>, Eylea<sup>®</sup> HD) and its biosimilars [aflibercept-mrbb (Ahzantive<sup>™</sup>), aflibercept-abzv (Enzeevu<sup>™</sup>), aflibercept-boav (Eydenzelt<sup>®</sup>), aflibercept-yszy (Opuviz<sup>™</sup>), aflibercept-ayyh (Pavblu<sup>™</sup>), aflibercept-jbvf (Yesafili<sup>™</sup>)] are vascular endothelial growth factor (VEGF) inhibitors.

**FDA Approved Indication(s)**

	nAMD	DME	DR	RVO	ROP
Eylea	x	x	x	x	x
Eylea HD	x	x	x	x	-
Ahzantive	x	x	x	x	-
Enzeevu	x	x	x	x	-
Eydenzelt	x	x	x	x	-
Opuviz	x	x	x	x	-
Pavblu	x	x	x	x	-
Yesafili	x	x	x	x	-

*nAMD=neovascular (wet) age-related macular degeneration; DME=diabetic macular edema; DR=diabetic retinopathy; RVO=macular edema following retinal vein occlusion; ROP=retinopathy of prematurity*

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Eylea, Eylea HD, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, and Yesafili are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Adult Ophthalmic Diseases (must meet all):**

1. Diagnosis of one of the following (a, b, c, or d):
  - a. nAMD;
  - b. DME;

- c. DR;
- d. Macular edema following RVO
- 2. Prescribed by or in consultation with an ophthalmologist;
- 3. Age  $\geq$  18 years;
- 4. For all indications, except for DME in members with baseline best corrected visual acuity (BCVA) 20/50 or worse: Failure of bevacizumab<sup>^</sup> intravitreal solution, unless contraindicated or clinically significant adverse effects are experienced;\*  
*<sup>^</sup>Prior authorization may be required for bevacizumab intravitreal solution. Requests for IV formulations of Avastin, Mvasi, and Zirabev will not be approved.*  
*\*For Illinois HIM requests, the step therapy requirements above do not apply per IL HB 5395*
- 5. Dose does not exceed one of the following (a or b):
  - a. For Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, and Yesafili, one of the following (i, ii, or iii):
    - i. nAMD: 2 mg (1 vial/syringe) every 4 weeks for the first 3 months, then every 8 weeks thereafter;
    - ii. DME and DR: 2 mg (1 vial/syringe) every 4 weeks for the first 5 injections, then every 8 weeks thereafter;
    - iii. RVO: 2 mg (1 vial/syringe) every 4 weeks;
  - b. For Eylea HD, one of the following (i, ii, or iii):
    - i. nAMD and DME: 8 mg (1 vial) every 4 weeks for the first 3 doses, followed by 8 mg (1 vial) every 8-16 weeks thereafter;
    - ii. DR: 8 mg (1 vial) every 4 weeks for the first 3 doses, followed by 8 mg (1 vial) every 8-12 weeks thereafter;
    - iii. RVO: 8 mg (1 vial) every 4 weeks for the first 3 to 5 doses, followed by 8 mg (1 vial) every 8 weeks thereafter.

**Approval duration: 6 months**

**B. Retinopathy of Prematurity (must meet all):**

- 1. Request is for Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, or Yesafili;
- 2. Diagnosis of ROP with one of the following retinal findings (a, b, or c):
  - a. Zone I stage 1+, 2+, 3, or 3+;
  - b. Zone II stage 2+ or 3+;
  - c. Aggressive posterior ROP (AP-ROP);
- 3. Prescribed by or in consultation with an ophthalmologist;
- 4. Member meets both of the following (a and b):
  - a. Gestational age at birth  $\leq$  32 weeks OR birth weight  $\leq$  1,500 g;
  - b. Body weight  $>$  800 g on day of treatment initiation;
- 5. Failure of bevacizumab intravitreal solution<sup>^</sup>, unless contraindicated or clinically significant adverse effects are experienced;\*  
*<sup>^</sup>Prior authorization may be required for bevacizumab intravitreal solution. Requests for IV formulations of Avastin, Mvasi, and Zirabev will not be approved.*  
*\*For Illinois HIM requests, the step therapy requirements above do not apply per IL HB 5395*
- 6. Dose does not exceed both of the following (a and b):
  - a. 0.4 mg one time, followed by an optional second and third dose of 0.4 mg at least 10 days apart for the same eye;
  - b. 3 doses per eye per lifetime.

**Approval duration: 6 months**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Adult Ophthalmic Diseases (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by one of the following (a, b, c, or d):
  - a. Detained neovascularization;
  - b. Improvement/stabilization in visual acuity;
  - c. Maintenance of corrected visual acuity from prior treatment;
  - d. Supportive findings from optical coherence tomography or fluorescein angiography;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
  - a. For Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, and Yesafili, one of the following (i or ii):
    - i. nAMD, DME and DR: One of the following (1 or 2):
      - 1) Dose does not exceed 2 mg (1 vial/syringe) every 8 weeks;
      - 2) Member meets both of the following (a and b):
        - a) Documentation supports evidence of continued disease activity;
        - b) New dose does not exceed 2 mg (1 vial/syringe) every 4 weeks;
    - ii. RVO: 2 mg (1 vial/syringe) every 4 weeks;
  - b. For Eylea HD, one of the following (i, ii, or iii):
    - i. nAMD and DME: One of the following (1 or 2):

- 1) Dose does not exceed 8 mg (1 vial) every 16 weeks;
- 2) Member meets both of the following (a and b):
  - a) Documentation supports evidence of continued disease activity;
  - b) New dose does not exceed 8 mg (1 vial) every 4 weeks;
- ii. DR: One of the following (1 or 2):
  - 1) Dose does not exceed 8 mg (1 vial) every 12 weeks;
  - 2) Member meets both of the following (a and b):
    - a) Documentation supports evidence of continued disease activity;
    - b) New dose does not exceed 8 mg (1 vial) every 4 weeks;
- iii. RVO: One of the following (1 or 2):
  - 1) Dose does not exceed 8 mg (1 vial) every 8 weeks;
  - 2) Member meets both of the following (a and b):
    - a) Documentation supports evidence of continued disease activity;
    - b) New dose does not exceed 8 mg (1 vial) every 4 weeks.

**Approval duration: 12 months**

**B. Retinopathy of Prematurity**

1. Reauthorization beyond the first three doses is not permitted. Member must meet initial approval criteria.

**Approval duration: Not applicable**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

- |                                    |  |
|------------------------------------|--|
| AP: aggressive posterior           | nAMD: neovascular (wet) age-related macular degeneration |
| BCVA: best corrected visual acuity | ROP: retinopathy of prematurity                          |
| DME: diabetic macular edema        | RVO: retinal vein occlusion                              |
| DR: diabetic retinopathy           | VEGF: vascular endothelial growth factor                 |
| FDA: Food and Drug Administration  |  |

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
bevacizumab (Avastin <sup>®</sup> )	<b>nAMD<sup>†</sup>:</b> 1.25 mg administered by intravitreal injection every 4 weeks.	1.25 mg/month
	<b>Macular edema secondary to RVO<sup>†</sup>:</b> 1.25 mg administered by intravitreal injection every 4 weeks	1.25 mg/month
	<b>DR<sup>†</sup>:</b> 1.25 mg administered by intravitreal injection every 6 weeks	1.25 mg/6 weeks
	<b>DME<sup>†</sup>:</b> 1.25 to 1.5 mg administered by intravitreal injection every 4 weeks	1.5 mg/month
	<b>ROP<sup>†</sup>:</b> Varies depending treatment regimen (i.e., followed by vitrectomy, laser therapy)	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*<sup>†</sup>Off-label*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s):
  - Ocular or periocular infection
  - Active intraocular inflammation
  - Hypersensitivity
- Boxed warning(s): none reported

*Appendix D: General Information*

- In the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (VIEW)-1 trial, the difference in the number of patients who lost fewer than 15 letters at 52 weeks between Eylea every 8 weeks compared to Lucentis was 0.6% (95.1% CI -0.32, 4.4). In terms of the number of patients who gained at least 15 letters,

the mean difference between Eylea every 8 weeks was 6.6% (95.1% CI -1.0, 14.1). There were no adverse events that were found to be significant from the Lucentis arm.

- In a trial comparing Eylea, Avastin and Lucentis, the Diabetic Retinopathy Clinical Research Network found in patients with diabetic macular edema that when the initial visual-acuity letter score was 78 to 69 (equivalent to approximately 20/32 to 20/40) (51% of participants), the mean improvement was 8.0 with Eylea, 7.5 with Avastin, and 8.3 with Lucentis ( $p > 0.50$  for each pair wise comparison). When the initial letter score was less than 69 (approximately 20/50 or worse), the mean improvement was 18.9 with Eylea, 11.8 with Avastin, and 14.2 with Lucentis ( $p < 0.001$  for Eylea vs. Avastin,  $p = 0.003$  for Eylea vs. Lucentis, and  $p = 0.21$  for Lucentis vs. Avastin).
- In clinical trials for the treatment of nAMD, DME, and DR, additional efficacy was not demonstrated in most patients when Eylea was dosed every 4 weeks as a maintenance dose, compared to every 8 weeks. Maintenance dosing at every 8 weeks should be attempted before increasing the intravitreal injection frequency to every 4 weeks.
- In Eylea HD PULSAR and PHOTON studies of patients with nAMD and DME, patients could be treated as frequently as every 8 weeks based on protocol-defined visual and anatomic criteria, starting at week 16. For both the every 12 week- and every 16 week- Eylea HD treated groups, treatments were shown to be non-inferior and clinically equivalent to Eylea 2mg every 8 week treatment with respect to the change in BCVA score at week 48 using the pre-specified non-inferiority margin of 4 letters.
- From the Eylea HD PHOTON study, DR data was derived to support FDA approval for continued dosing every 8 to 12 weeks following the first 3 doses. For this measure, the group that received Eylea HD every 12 weeks met the noninferiority margin of 10% in comparison to Eylea 2 mg every 8 weeks; however, the group that received Eylea HD every 16 weeks did not.

## V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Aflibercept (Eylea) and biosimilars (Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, Yesafili)	nAMD	2 mg (1 vial/syringe) administered by intravitreal injection once a month for 3 months then 2 mg every 2 months  <i>Although aflibercept may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months).</i>	2 mg/month
	Macular edema following RVO	2 mg (1 vial/syringe) administered by intravitreal injection once every 4 weeks (monthly)	2 mg/month

Drug Name	Indication	Dosing Regimen	Maximum Dose
	DME, DR	<p>2 mg (1 vial/syringe) administered by intravitreal injection once a month for the first 5 injections, followed by 2 mg via intravitreal injection once every 2 months</p> <p><i>Although aflibercept may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).</i></p>	2 mg/month
Aflibercept (Eylea)	ROP	0.4 mg administered by intravitreal injection once, followed by an optional two additional doses spaced at least 10 days apart for the same eye.	0.4 mg/dose
Aflibercept (Eylea HD)	nAMD, DME	<p>8 mg administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks, +/- 1 week</p> <p><i>Some patients did not maintain a response with extended dosing intervals after successful response to the three initial monthly doses. These patients may benefit from resuming every 4-week dosing (approximately every 28 days +/- 7 days).</i></p>	8 mg/dose
	DR	<p>8 mg administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg via intravitreal injection once every 8 to 12 weeks, +/- 1 week</p> <p><i>Some patients did not maintain a response with extended dosing intervals after successful response to the three initial monthly doses. These patients may benefit from resuming every 4-week dosing (approximately every 28 days +/- 7 days).</i></p>	8 mg/dose

Drug Name	Indication	Dosing Regimen	Maximum Dose
	RVO	8 mg administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three to five doses, followed by 8 mg via intravitreal injection once every 8 to 8 weeks, +/- 1 week  <i>Some patients did not maintain a response with extended dosing intervals after successful response to the three initial monthly doses. These patients may benefit from resuming every 4-week dosing (approximately every 28 days +/- 7 days).</i>	8 mg/dose

## VI. Product Availability

Drug Name	Availability
Aflibercept (Eylea)	Single-dose vial and pre-filled syringe for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution
Aflibercept (Eylea HD)	Single-dose vial for intravitreal injection: 8 mg (0.07 mL of 114.3 mg/mL solution)
Aflibercept-mrbb (Ahzantive)	Single-dose vial for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution
Aflibercept-abzv (Enzeevu)	Single-dose vial and pre-filled syringe for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution
Aflibercept-boav (Eydenzelt)	Single-dose vial and pre-filled syringe for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution
Aflibercept-yszy (Opuviz)	Single-dose vial for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution
Aflibercept-ayyh (Pavblu)	Single-dose vial and pre-filled syringe for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution
Aflibercept-jbvf (Yesafili)	Single-dose vial and pre-filled syringe for intravitreal injection: 2 mg (0.05 mL of 40 mg/mL) solution

## VII. References

1. Eylea Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; October 2024 Available at: [https://www.regeneron.com/downloads/eylea\\_fpi.pdf](https://www.regeneron.com/downloads/eylea_fpi.pdf). Accessed October 29, 2025.
2. Eylea HD Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; November 2025 Available at: <https://eyleahdhcp.com>. Accessed November 21, 2025.
3. Ahzantive Prescribing Information. Martinsried, Germany: Formycon AG.; June 2024 Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/761378s0001b1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761378s0001b1.pdf). Accessed October 29, 2025.

4. Enzeevu Prescribing Information. Princeton, NJ: Sandoz; February 2026. Available at: [https://sandoz-com.cms.sandoz.com/sites/default/files/Media%20Documents/SOK583\\_BS\\_A\\_1.14.1.3\\_prescribing-information-Enzeevu.pdf?\\_gl=1\\*1uespwp\\*\\_gcl\\_au\\*MTI3Mzc4NDcwOC4xNzcwODY1OTM4%20%20%20](https://sandoz-com.cms.sandoz.com/sites/default/files/Media%20Documents/SOK583_BS_A_1.14.1.3_prescribing-information-Enzeevu.pdf?_gl=1*1uespwp*_gcl_au*MTI3Mzc4NDcwOC4xNzcwODY1OTM4%20%20%20). Accessed February 18, 2026.
5. Eydenzelt Prescribing Information. Jersey City, NJ: Celltrion USA Inc; October 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761377s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761377s0001bl.pdf). Accessed October 29, 2025.
6. Aflibercept-yszy Prescribing Information. Cambridge, MA: Biogen MA Inc.; August 2025 Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761350s0071bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761350s0071bl.pdf). Accessed October 29, 2025.
7. Pavblu Prescribing Information. Thousand Oaks, CA: Amgen; August 2024. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/761298s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761298s0001bl.pdf). Accessed October 29, 2025.
8. Yesafili Prescribing Information. Cambridge, MA: Biocon Biologics Inc.; January 2026 Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2026/761274s0011bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761274s0011bl.pdf). Accessed January 28, 2026.
9. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern<sup>®</sup> Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; September 2024. Available at: [www.aao.org/ppp](http://www.aao.org/ppp). Accessed October 29, 2025.
10. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern<sup>®</sup> Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; September 2024. Available at: [www.aao.org/ppp](http://www.aao.org/ppp). Accessed October 29, 2025.
11. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern<sup>®</sup> Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; September 2024. Available at: [www.aao.org/ppp](http://www.aao.org/ppp). Accessed October 29, 2025.
12. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*. 2015 Mar 26;372(13):1193-203. Doi: 10.1056/NEJMoa1414264.
13. Walter M. Fierson, American Academy of Pediatrics section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists, et al., Screening Examination of Premature Infants for Retinopathy of Prematurity. *Pediatrics* December 2018; 142 (6): e20183061. 10.1542/peds.2018-3061
14. Scott IU, VanVeldhuisen PC, Ip MS, et al; SCORE2 Investigator Group. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. *JAMA*. 2017 May 23;317(20):2072-2087. doi: 10.1001/jama.2017.4568.
15. Clinical Pharmacology [database online]. Tampa, FL: Elsevier; 2025. URL: [www.clinicalkeys.com/pharmacology](http://www.clinicalkeys.com/pharmacology).

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0178	Injection, aflibercept, 1 mg
J0177	Injection, aflibercept hd, 1 mg
Q5147	Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg
Q5149	Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg
Q5150	Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg
Q5153	Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg
Q5155	Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
Q5170	Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: no significant changes; references reviewed and updated.	11.09.21	02.22
Added legacy WellCare line of business (WCG.CP.PHAR.184 to be retired) and shortened approval durations from 12 months to 6 months.	01.26.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.03.22	
1Q 2023 annual review: no significant changes; clarified initial criteria from “worse than” to state BCVA 20/50 “or worse”; references reviewed and updated.	10.18.22	02.23
RT4: added criteria for newly FDA-approved indication of ROP; references reviewed and updated.	04.12.23	05.23
RT4: added new Eylea HD formulation; for macular edema following RVO and ROP indications, added criteria that request is for Eylea; for continued use of Eylea in DME and DR, added option for every 4 week dosing to align with nAMD; references reviewed and updated.	09.13.23	
1Q 2024 annual review: no significant changes; added HCPCS codes for Eylea HD [J3590, C9399]; references reviewed and updated.	11.02.23	02.24
Added HCPCS code [J0177] and removed HPCS codes [J3590, C9399].	02.21.24	
Ad Hoc update: for section V, clarified typo for Eylea HD maximum dose from 0.8 mg to 8 mg	04.02.24	
RT4: added Eylea biosimilars Opuviz, Yesafili, and Ahzantive; separated macular edema following RVO into new section with specification that request is for Eylea, Opuviz, Yesafili, or Ahzantive.	07.05.24	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
RT4: added new Eylea biosimilars Enzeevu and Pavblu; expanded ROP indication criteria to also allow use of the biosimilars – Opuviz, Yesafili, Ahzantive, Enzeevu, and Pavblu.	09.10.24	
1Q 2025 annual review: added max dose of 1 vial or syringe to Eylea and Enzeevu criteria; in Appendix B per Clinical Pharmacology, updated dosing regimens and clarified off-label indications; references reviewed and updated.	11.15.24	02.25
HCPCS codes added [Q5147, Q5149, Q5150].	02.13.25	
HCPCS code added [Q5153].	05.16.25	
HCPCS code added [Q5155].	09.11.25	
RT4: added new Eylea biosimilar Eydenzelt.	10.08.25	
1Q 2026 annual review: combined RVO section with nAMD, DME, and DR section; added step therapy bypass for IL HIM per IL HB 5395; for adult ophthalmic diseases, extended continued therapy duration from 6 months to 12 months for this maintenance medication for a chronic condition; for ROP, clarified 3 lifetime doses per eye; references reviewed and updated. RT4: for Eylea HD, added criteria for newly FDA-approved indication of RVO; in continued therapy, added option for every 4 week dosing if documentation supports evidence of continued disease activity. RT4: added newly approved pre-filled syringe formulation for Yesafili.	01.28.26	02.26
RT4: for Enzeevu, updated FDA-approved indications to include DME, DR, and RVO per prescribing information.	02.18.26	
Added HCPCS code Q5170.	06.02.26	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,

contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members, and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.